Translating Clinical Trial Evidence to Routine Practice—How Do We Overcome the Barriers?
Menée aux Etats-Unis à partir de données portant sur 2 833 patients atteints d'un cancer du poumon non à petites cellules de stade IB à IIIA (âge moyen : 66,5 ans), cette étude analyse l'adéquation entre les traitements reçus (résection chirurgicale, curage ganglionnaire et chimiothérapie adjuvante) et les recommandations du "National Comprehensive Cancer Network"
In early-stage non–small cell lung cancer (NSCLC), surgery followed by adjuvant platinum-based chemotherapy has remained the backbone treatment for many decades. Recent trials also define the roles of adjuvant osimertinib and atezolizumab for different patient subgroups. Improvements in cancer outcomes rely not only on randomized clinical trials to generate evidence for the efficacy of novel therapies but are also contingent on that evidence being incorporated into guidelines that are then adopted in routine practice. Accurate capture of real-world cancer treatment is a critical step in evaluating the translation of evidence-based treatment guidelines to routine care to ensure best practice and improve outcomes at a population level.
JAMA Oncology , éditorial, 2021